Angus G Jones

List of Publications by Year
in descending order

75 papers	**3,366** citations	186265 **28** h-index	161849 **54** g-index
83 all docs	**83** docs citations	**83** times ranked	**4499** citing authors

#	Article	IF	Citations
1	Mortality amongst children and adolescents with type 1 diabetes in <scp>sub‑Saharan</scp> Africa: The case study of the Changing Diabetes in Children program in Cameroon. Pediatric Diabetes, 2022, 23, 33-37.	2.9	6
2	Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study. Cell Reports Medicine, 2022, 3, 100477.	6.5	39
3	Understanding the pathogenesis of lean non-autoimmune diabetes in an African population with newly diagnosed diabetes. Diabetologia, 2022, 65, 675-683.	6.3	16
4	Is glycaemic control associated with dietary patterns independent of weight change in people newly diagnosed with type 2 diabetes? Prospective analysis of the Early-ACTivity-In-Diabetes trial. BMC Medicine, 2022, 20, 161.	5.5	2
5	Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2022, 10, e002714.	2.8	2
6	Diagnosing Type 1 diabetes in adults: Guidance from the UK T1D Immunotherapy consortium. Diabetic Medicine, 2022, 39, e14862.	2.3	6
7	Islet autoantibody positivity in an adult population with recently diagnosed diabetes in Uganda. PLoS ONE, 2022, 17, e0268783.	2.5	0
8	T-Cell Autoreactivity in Type 2 Diabetes: Benign or Pathogenic, Smoke or Fire?. Diabetes, 2022, 71, 1167-1169.	0.6	1
9	Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 80-90.	3.6	5
10	Associations between low HDL, sex and cardiovascular risk markers are substantially different in sub-Saharan Africa and the UK: analysis of four population studies. BMJ Global Health, 2021, 6, e005222.	4.7	8
11	Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care, 2021, 44, 1243-1251.	8.6	52
12	Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study. BMC Medicine, 2021, 19, 184.	5.5	5
13	Zinc transporter 8 autoantibody testing requires age-related cut-offs. BMJ Open Diabetes Research and Care, 2021, 9, e002296.	2.8	4
14	HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2021, 9, e002350.	2.8	5
15	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2021, 44, 511-518.	8.6	16
16	Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. Diabetes Care, 2021, 44, 2449-2456.	8.6	73
17	Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus – A MASTERMIND precision medicine approach (UKPDS 87). Diabetes Research and Clinical Practice, 2020, 166, 108333.	2.8	3
18	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. Genome Medicine, 2020, 12, 109.	8.2	8

#	Article	IF	Citations
19	A reference map of potential determinants for the human serum metabolome. Nature, 2020, 588, 135-140.	27.8	230
20	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. EBioMedicine, 2020, 58, 102932.	6.1	3
21	Comparison of oral glucose tolerance test and ambulatory glycaemic profiles in pregnant women in Uganda with gestational diabetes using the FreeStyle Libre flash glucose monitoring system. BMC Pregnancy and Childbirth, 2020, 20, 635.	2.4	7
22	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Medicine, 2020, 17, e1003149.	8.4	47
23	Logistic regression has similar performance to optimised machine learning algorithms in a clinical setting: application to the discrimination between type 1 and type 2 diabetes in young adults. Diagnostic and Prognostic Research, 2020, 4, 6.	1.8	69
24	Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes. Diabetic Medicine, 2020, 37, 2160-2168.	2.3	15
25	The challenge of diagnosing type 1 diabetes in older adults. Diabetic Medicine, 2020, 37, 1781-1782.	2.3	5
26	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research and Care, 2020, 8, e001238.	2.8	43
27	TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. BMJ Open, 2020, 10, e042784.	1.9	17
28	Title is missing!. , 2020, 17, e1003149.		0
29	Title is missing!. , 2020, 17, e1003149.		0
30	Title is missing!. , 2020, 17, e1003149.		0
31	Title is missing!. , 2020, 17, e1003149.		0
32	Title is missing!. , 2020, 17, e1003149.		0
33	Clusters provide a better holistic view of type 2 diabetes than simple clinical features – Authors' reply. Lancet Diabetes and Endocrinology,the, 2019, 7, 669.	11.4	3
34	Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. Journal of Hepatology, 2019, 71, 594-602.	3.7	23
35	Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes and Endocrinology,the, 2019, 7, 442-451.	11.4	280
36	Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by *SLC29A4*) and Organic Cation Transporter 1 (OCT1) (Encoded by *SLC22A1*) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2019, 42, 1027-1033.	8.6	43

#	Article	IF	Citations
37	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010â€"2017. Diabetes, Obesity and Metabolism, 2019, 21, 1576-1584.	4.4	64
38	Understanding the manifestation of diabetes in sub Saharan Africa to inform therapeutic approaches and preventive strategies: a narrative review. Clinical Diabetes and Endocrinology, 2019, 5, 2.	2.7	54
39	Persistent Câ€peptide is associated with reduced hypoglycaemia but not HbA$_{1c}$ in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabetic Medicine, 2019, 36, 1092-1099.	2.3	32
40	Type 1 diabetes defined by severe insulin deficiency occurs after 30Âyears of age and is commonly treated as type 2 diabetes. Diabetologia, 2019, 62, 1167-1172.	6.3	100
41	What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Medicine, 2019, 17, 79.	5.5	10
42	Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18â€"50 years. BMJ Open, 2019, 9, e031586.	1.9	49
43	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibodyâ€"Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes Care, 2019, 42, 208-214.	8.6	35
44	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	8.6	67
45	Comment on: â€œDulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A postâ€hoc analysis of the AWARDâ€2, â^’4 and â^’5 trialsâ€. Diabetes, Obesity and Metabolism, 2018, 20, 1549-1550.	4.4	1
46	Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 2018, 61, 66-74.	6.3	30
47	Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. Clinical Epidemiology, 2018, Volume 10, 1869-1877.	3.0	14
48	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care, 2018, 41, 1844-1853.	8.6	91
49	Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes, Obesity and Metabolism, 2018, 20, 2159-2168.	4.4	63
50	Current laboratory requirements for adrenocorticotropic hormone and renin/aldosterone sample handling are unnecessarily restrictive. Clinical Medicine, 2017, 17, 18-21.	1.9	13
51	Sustained influence of metformin therapy on circulating glucagonâ€like peptideâ€1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 356-363.	4.4	47
52	Markers of Î²-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care, 2016, 39, 250-257.	8.6	132
53	Random nonâ€fasting Câ€peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabetic Medicine, 2016, 33, 1554-1558.	2.3	50
54	Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis. British Journal of General Practice, 2016, 66, e315-e322.	1.4	60

#	ARTICLE	IF	CITATIONS
55	A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 2016, 39, 337-344.	8.6	231
56	Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. PLoS ONE, 2016, 11, e0152428.	2.5	26
57	Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open, 2015, 5, e009088.	1.9	81
58	Effect of the Holiday Season in Patients With Diabetes: Glycemia and Lipids Increase Postholiday, but the Effect Is Small and Transient. Diabetes Care, 2014, 37, e98-e99.	8.6	9
59	The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 2014, 57, 187-191.	6.3	240
60	Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine. PLoS ONE, 2014, 9, e111235.	2.5	12
61	Preoperative Endocrine Function and Fluid Electrolyte Balance. , 2014, , 95-105.		0
62	The clinical utility of Câ€peptide measurement in the care of patients with diabetes. Diabetic Medicine, 2013, 30, 803-817.	2.3	455
63	Practical implications of choice of test in National Institute for Health and Clinical Excellence (<scp>NICE</scp>) guidance for the prevention of TypeÂ2 diabetes. Diabetic Medicine, 2013, 30, 126-127.	2.3	3
64	Urinary Câ€peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabetic Medicine, 2013, 30, 1342-1348.	2.3	13
65	The impact of gender on urine C-peptide creatinine ratio interpretation. Annals of Clinical Biochemistry, 2012, 49, 363-368.	1.6	17
66	Phaeochromocytoma. BMJ: British Medical Journal, 2012, 344, e1042-e1042.	2.3	4
67	The impact of insulin administration during the mixed meal tolerance test. Diabetic Medicine, 2012, 29, 1279-1284.	2.3	19
68	Assessment of endogenous insulin secretion in insulin treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocrine Disorders, 2012, 12, 6.	2.2	14
69	A novel case of a raised testosterone and LH in a young man. Clinica Chimica Acta, 2011, 412, 1999-2001.	1.1	2
70	A woman with episodic headaches, sweating, and palpitations. BMJ: British Medical Journal, 2011, 342, d2977-d2977.	2.3	0
71	Urine Câ€peptide creatinine ratio is an alternative to stimulated serum Câ€peptide measurement in lateâ€onset, insulinâ€treated diabetes. Diabetic Medicine, 2011, 28, 1034-1038.	2.3	32
72	Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes. Diabetes Care, 2011, 34, 607-609.	8.6	62

#	Article	IF	Citations
73	Reevaluation of a case of type 1 diabetes mellitus diagnosed before 6 months of age. Nature Reviews Endocrinology, 2010, 6, 347-351.	9.6	7
74	Specific Câ€Terminal Cleavage and Inactivation of Interleukinâ€8 by Invasive Disease Isolates of<i>Streptococcus pyogenes</i>. Journal of Infectious Diseases, 2005, 192, 783-790.	4.0	175
75	Post-meal Urinary C-peptide creatinine ratio is a moderate measure of insulin secretion in diabetes patients in Cameroon: results from a cross-sectional study. PAMJ Clinical Medicine, 0, 3, .	0.0	2